Enclosed Financial Result for the First quarter ended 30th June 2026 together with Limited Review Report as submitted by Statutory auditor

To To Date: August 12, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Unaudited Standalone and Consolidated Financial Results for the First Quarter ended on 30th June, 2026 along with the Limited Review Report. Dear Sir/Madam, We herewith enclosed the Unaudited Standalone and Consolidated Financial Results of the Company for the First quarter ended on 30th June, 2026 (Q1/2026-27) as approved by the Board of Directors together with the Limited Review Report as submitted by the Statutory Auditors. The meeting commenced at 04.45 PM and concluded at 05.15 PM on Wednesday, August 12, 2026. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681 Corporate Office ©) +9180 4137 9500 BAL PHARMA LIMITED © info@balpharma.com ro) Sth Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India. To Date: August 12, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot Ng. C/2, G Block, Rotunda Building, P.]. Towers; Bandra Kurla Complex, Bandra (I), Dalal Street, Mumbai-400051 Mumbai - 400001 Symbol: BALPHARMA Scrip Code: 524824. Sub: Non applicability of statement of Deviation/ Variation Ref: Regulation 32(1) of SEBI (LODR) Regulations 2015. Dear Sir/Madam, With reference to the above cited subject and reference, we would like to clarify that as the Company has neither raised any funds through public issue, rights issue, preferential issue, QIP etc nor has any proceeds of the earlier issues outstanding for utilization for the quarter ended 30.06.2026, filing of statement of deviation/variation in utilization of funds raised is not applicable to the Company, for the above said quarter. Please takes this intimation on your records Thanking You. For Bal Pharma Limited ailesh Siroya Managing Director DIN : 00048109 Registered Office : Plot No. 2] & 22, Bommasandra Industrial Area, Bengaluru - 560 099, Karnataka, INDIA. Ph: +91 80 41570811/813. CIN # L85IOKAIS87PLCO08368 ) Www. balpharma.com Corporate Office BAL PHARMA LIMITED ©© i+n9f1o8e0s 4 b1 e3 l7 p h9 a5 r0 m0 e .com 9) 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India. To To Date: August 12, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, PJ. Towers, Bandra Kurla Complex, Bandra (EB), Dalal Street, Mumbai-4.00051 Mumbai - 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Declaration of Unmodified Opinion on Audited Financial Results for the quarter and financial year ending 30.06.2026 Dear Sir/Madam, Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the statutory auditors of the Company M/s. SSJNB & Co, Chartered Accountants, having membership # 00139768 have issued their limited review report with Unmodified opinion on audited Standalone and Consolidated Financial results of the Company, for the quarter and financial year ended 30 June 2026. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shailesh Siroya Managing Director * DIN: 00048109 — Registered Office : Plot No. 21 & 22, Bommasandra Industrial Area, Bengaluru - SGO 099. Karnataka, INDIA, Ph: +91 80 41570811/813. CIN # L8511IOKAI987PLCO084368 6) www. balpharma.com S S J N B & Co Chartered Accountants Landline: 080-4977 7951 / 52 / 53 / 54 Email: office@ssjnb.in Independent Auditor’s review report on the Quarterly and year to date unaudited standalone financial results of Bal Pharma Limited pursuant to the Regulation 33 of SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, as amended To the Board of Directors of Bal Pharma Limited We have reviewed the accompanying statement of unaudited standalone financial results of Bal Pharma Limited (“the Company”) for the quarter ended 30th June 2026 and the year to date from 1st April 2026 to 30th June 2026 (the “Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended. This Statement, which is the responsibility of the Company’s Management and which has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial reporting “(“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the statement based on our review. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information performed by the Independent auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A Review is substantially less in scope than an audit conducted in accordance with Standards of Auditing and consequently does not enable us to obtain assurance that we have become aware of all significant matters that may be identified in an audit. Accordingly, we do not express an audit opinion. No.79/5, 2nd and 3rd Floor, Sri Lakshmi Venkateshwara Complex, Vani Vilas Road, Basavanagudi, Bengaluru, Karnataka, 560004 S S J N B & Co Chartered Accountants Landline: 080-4977 7951 / 52 / 53 / 54 Email: office@ssjnb.in Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (“Ind AS”) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and disclosure Requirements ) Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M/s. S S J N B & Co Chartered Accountants Firm registration number: 013976S Dhanpal I Sakaria Partner Membership No: 213666 UDIN: 26213666AAQBBY4418 Place: Bengaluru Date: 12 August 2026 No.79/5, 2nd and 3rd Floor, Sri Lakshmi Venkateshwara Complex, Vani Vilas Road, Basavanagudi, Bengaluru, Karnataka, 560004 BAL PHARMA LIMITED CIN: L85110KA1987PLC008368 Regd.Office: 21-22 Bommasandra Industrial Area,Anekal Taluq,Bangalore 560 099 STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2026 in Rs. Lakhs Sl No. Particulars Quarter Ended Year ended 30-Jun-2026 31-Mar.2026 30-Jun-2025 3Y1e-aMr aEr-n2d0e2d6 Unaudited Audited Unaudited Audited Income I Revenue from operations 8 ,842.73 8 ,391.76 6 ,563.51 3 1,079.70 II Other income 45.71 -21.82 74.11 2 00.29 III Total Income - (I)+(II) 8 ,888.44 8 ,369.95 6 ,637.62 3 1,279.99 IV Expenses a) Cost of materials consumed 4 ,847.25 4 ,113.65 3 ,602.85 1 6,096.74 b) Purchase of Stock-in-trade 2 [Showing first 8,000 characters — download PDF for full document]